Proteome Sciences PLC (GB:PRM)
LSE:PRM
Want to see GB:PRM full AI Analyst Report?
PRM Stock Chart & Stats
2.85 p
-0.10 p(-2.84%)
At close: 4:00 PM EST
2.85 p
-0.10 p(-2.84%)
Day’s Range― - ―
52-Week Range1.20 p - 4.40 p
Previous CloseN/A
Volume41.42K
Average Volume (3M)476.64K
Market Cap
£4.84M
Enterprise Value19.29M
Total Cash (Recent Filing)£781.00K
Total Debt (Recent Filing)£15.77M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume209,671
30 Day Avg. Volume476,642
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Proteomics FocusProteome Sciences’ specialized focus on proteomics and mass-spectrometry analytics is a durable competitive advantage. Deep scientific expertise, tailored workflows and domain knowledge create high technical barriers to entry and support long-term demand from drug discovery and biomarker programs.
Contract Research Business ModelA services-driven model selling contracted projects to pharma, biotech and academia supports recurring project pipelines and long sales lifecycles. Durable client relationships and project-based revenue enable predictable workstreams and recurring demand tied to R&D budgets rather than transactional product cycles.
Improving Near-term Cash GenerationCash flow materially improved in 2025 versus prior years, with operating cash near break-even and much smaller negative free cash flow. That trend reduces immediate refinancing pressure and indicates operational adjustments that can support sustainability if sustained over multiple quarters.
Bears Say
Strained Balance SheetHigh gross debt alongside deeply negative equity signals limited balance-sheet flexibility and elevated solvency risk. Assets are reported well below liabilities, making refinancing or capital raises likely and increasing the risk of dilution or restructuring that can impair long-term operations and stakeholder value.
Persistent Profitability DeteriorationA drop in revenue with negative gross profit and widening operating losses indicates weak cost absorption and structural margin pressure. Continued losses limit reinvestment capacity, hamper ability to win larger contracts, and lengthen the timeline to sustainable profitability absent structural changes.
Volatile And Negative Free Cash Flow HistoryHistoric swings in cash flow and persistent negative free cash flow undermine long-term planning and increase reliance on external financing. Volatility raises the probability of periodic funding needs, which can dilute shareholders or constrain strategic investments when markets tighten.
Proteome Sciences News
PRM FAQ
What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest share price was 1.20 p and its highest was 4.40 p in the past 12 months.
What is Proteome Sciences PLC’s market cap?
Proteome Sciences PLC’s market cap is £4.84M.
When is Proteome Sciences PLC’s upcoming earnings report date?
Proteome Sciences PLC’s upcoming earnings report date is Aug 26, 2026 which is in 120 days.
How were Proteome Sciences PLC’s earnings last quarter?
Proteome Sciences PLC released its earnings results on Apr 15, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.
Is Proteome Sciences PLC overvalued?
According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued.
Does Proteome Sciences PLC pay dividends?
Proteome Sciences PLC does not currently pay dividends.
What is Proteome Sciences PLC’s EPS estimate?
Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteome Sciences PLC have?
Proteome Sciences PLC has 350,724,900 shares outstanding.
What happened to Proteome Sciences PLC’s price movement after its last earnings report?
Proteome Sciences PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Proteome Sciences PLC?
Currently, no hedge funds are holding shares in GB:PRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.
Technical Analysis
Options Prices
Currently, No data available
---